Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Team Work: Pfizer, Abbott Gain Swift Approvals For Lung Cancer Drug/Test Combo

This article was originally published in The Gray Sheet

Executive Summary

Following simultaneous and swift FDA approvals, Abbott Molecular Diagnostics is launching its Vysis ALK molecular test to identify the small percentage of non-small-cell lung cancer patients who would respond to Pfizer’s Xalkori (crizotinib) cancer drug.
Advertisement

Related Content

News Briefs: Siemens-Pfizer Dx Pact; Pancreatic Stent; AtriCure Acquisition
News In Brief
News In Brief
FDA Companion Dx Draft Guidance: Broad In Scope, Limited In Detail
Abbott Follows Pfizer To FDA With Co-Developed Lung Cancer Diagnostic
Fast As A Whip, Pfizer Files Personalized Lung Cancer Drug Crizotinib

Topics

Advertisement
UsernamePublicRestriction

Register

MT030511

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel